Insider · CIK 0001663022
Kate Haviland
ceoofficerdirector
Files at BPMC (Blueprint Medicines Corp), FULC (Fulcrum Therapeutics, Inc.), BCAX (Bicara Therapeutics Inc.). First filing Dec 3, 2024, latest Apr 3, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $2.0M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Blueprint Medicines Corp | $216k 2,498 shares | -1% | - | |
| 65Notable | Blueprint Medicines Corp | $1.4M 16,151 shares | -9% | - | |
| 31Weak | Blueprint Medicines Corp | $159k 1,446 shares | -1% | - | |
| 33Weak | Blueprint Medicines Corp | $227k 2,353 shares | -2% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | AGrant or award Common Stock | +129,210 | - | - | 295,139 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Common Stock | -224,410 | - | - | 70,729 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | UTender of shares Common Stock | -70,729 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -2 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -591 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -39,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -32,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -26,125 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -70,400 | - | - | 0 | Jul 21, 2025 |
| Jun 26, 2025 | FULC Fulcrum Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Jun 30, 2025 |
| Jun 9, 2025 | BCAX Bicara Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +23,746 | $0.00 | $0 | 23,746 | Jun 10, 2025 |
| Apr 1, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -600 | $85.47 | $51k | 167,827 | Apr 3, 2025 |
| Apr 1, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -598 | $86.14 | $52k | 167,229 | Apr 3, 2025 |
| Apr 1, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -1,200 | $87.34 | $105k | 166,029 | Apr 3, 2025 |
| Apr 1, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -100 | $88.59 | $8,859 | 165,929 | Apr 3, 2025 |
| Mar 5, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock | -16,151 | $88.80 | $1.4M | 168,427 | Mar 7, 2025 |
| Mar 1, 2025 | BPMC Blueprint Medicines Corp | AGrant or award Common Stock | +35,200 | $0.00 | $0 | 184,578 | Mar 4, 2025 |
| Mar 1, 2025 | BPMC Blueprint Medicines Corp | AGrant or award Stock Option (Right to Buy)derivative | +70,400 | $0.00 | $0 | 70,400 | Mar 4, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -1,446 | $110.24 | $159k | 149,378 | Jan 23, 2025 |
| Nov 29, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -400 | $95.40 | $38k | 152,777 | Dec 3, 2024 |
| Nov 29, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -1,746 | $96.74 | $169k | 151,031 | Dec 3, 2024 |
| Nov 29, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -207 | $97.76 | $20k | 150,824 | Dec 3, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.